Latest News & Updates | Lymphoma Canada Announcements

News

CLL & SLL Patient & Caregiver Surveys

If you have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) or you…

adminMay 25, 2017

News

CAR-T Cell Therapy Shows Promise in Aggressive NHL

Promising results from the phase 1 portion of a multi-center phase 1/2 clinical trial (ZUMA-1…

adminApril 4, 2017

News

Pembrolizumab may help those with relapsed NK-cell and T-cell lymphomas

A small study suggests that pembrolizumab may provide lasting remissions in some patients with NK-cell…

adminApril 4, 2017

News Research

Health Canada Approves GAZYVA® for Patients with Previously Treated Follicular Lymphoma

New targeted treatment now available for Canadians living with the most common form of slow-growing, non-Hodgkin's…

adminFebruary 13, 2017

News

BCCA Provincial Systemic Therapy Program approves new program

The BCCA Provincial Systemic Therapy Program approves Bendamustine With Rituximab for Previously Untreated CLL or…

adminJanuary 13, 2017

News Research

pCODR Final Recommendation Issued for idelalisib (Zydelig) for Follicular Lymphoma

On September 29, 2016, the pCODR Expert Review Committee (pERC) issued a final recommendation for…

adminDecember 16, 2016

News Research

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Waldenstrom’s Macroglobulinemia

On November 3, 2016, the pCODR Expert Review Committee (pERC) issued a final recommendation for…

adminDecember 16, 2016

News Research

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for First-line Treatment of CLL

On November 3, 2016, the pCODR Expert Review Committee (pERC) issued a final recommendation for…

adminDecember 16, 2016

News Research

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Mantle Cell Lymphoma (MCL)

On July 19, 2016, the pCODR Expert Review Committee (pERC) issued a final recommendation for…

adminDecember 16, 2016

News Research

Health Canada Approves Venetoclax for CLL Patients With 17P deletion or if No Other Treatment Options are Available

Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for VENCLEXTA™ (venetoclax), a…

adminDecember 16, 2016

Mon	Tue	Wed	Thu	Fri	Sat	Sun
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

News & Media

CLL & SLL Patient & Caregiver Surveys

CAR-T Cell Therapy Shows Promise in Aggressive NHL

Pembrolizumab may help those with relapsed NK-cell and T-cell lymphomas

Health Canada Approves GAZYVA® for Patients with Previously Treated Follicular Lymphoma

BCCA Provincial Systemic Therapy Program approves new program

pCODR Final Recommendation Issued for idelalisib (Zydelig) for Follicular Lymphoma

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Waldenstrom’s Macroglobulinemia

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for First-line Treatment of CLL

pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Mantle Cell Lymphoma (MCL)

Health Canada Approves Venetoclax for CLL Patients With 17P deletion or if No Other Treatment Options are Available

Are you a patient?

Are you a healthcare professional?

Upcoming Events

Contact Us

Donate

Careers

Join Our Mailing List